FASLG and neoplasm: In addition, we have reported that both galiximab (17) and rituximab (19–21) inhibit survival pathways in B-NHL cells leading to susceptibility of tumor cells to direct cytotoxicity by both chemotherapeutic drugs and by host immune effector cells bearing FasL or TRAIL.